Cargando…
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Research in cancer immunology is currently accelerating following a series of cancer immunotherapy breakthroughs during the last 5 years. Various monoclonal antibodies which block the interaction between checkpoint molecules PD-1 on immune cells and PD-L1 on cancer cells have been used to successful...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986262/ https://www.ncbi.nlm.nih.gov/pubmed/27532023 http://dx.doi.org/10.1186/s40425-016-0153-x |
_version_ | 1782448173558530048 |
---|---|
author | Grigg, Claud Rizvi, Naiyer A. |
author_facet | Grigg, Claud Rizvi, Naiyer A. |
author_sort | Grigg, Claud |
collection | PubMed |
description | Research in cancer immunology is currently accelerating following a series of cancer immunotherapy breakthroughs during the last 5 years. Various monoclonal antibodies which block the interaction between checkpoint molecules PD-1 on immune cells and PD-L1 on cancer cells have been used to successfully treat non-small cell lung cancer (NSCLC), including some durable responses lasting years. Two drugs, nivolumab and pembrolizumab, are now FDA approved for use in certain patients who have failed or progressed on platinum-based or targeted therapies while agents targeting PD-L1, atezolizumab and durvalumab, are approaching the final stages of clinical testing. Despite impressive treatment outcomes in a subset of patients who receive these immune therapies, many patients with NSCLC fail to respond to anti-PD-1/PD-L1 and the identification of a biomarker to select these patients remains highly sought after. In this review, we discuss the recent clinical trial results of pembrolizumab, nivolumab, and atezolizumab for NSCLC, and the significance of companion diagnostic testing for tumor PD-L1 expression. |
format | Online Article Text |
id | pubmed-4986262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49862622016-08-17 PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? Grigg, Claud Rizvi, Naiyer A. J Immunother Cancer Clinical Trials Monitor Research in cancer immunology is currently accelerating following a series of cancer immunotherapy breakthroughs during the last 5 years. Various monoclonal antibodies which block the interaction between checkpoint molecules PD-1 on immune cells and PD-L1 on cancer cells have been used to successfully treat non-small cell lung cancer (NSCLC), including some durable responses lasting years. Two drugs, nivolumab and pembrolizumab, are now FDA approved for use in certain patients who have failed or progressed on platinum-based or targeted therapies while agents targeting PD-L1, atezolizumab and durvalumab, are approaching the final stages of clinical testing. Despite impressive treatment outcomes in a subset of patients who receive these immune therapies, many patients with NSCLC fail to respond to anti-PD-1/PD-L1 and the identification of a biomarker to select these patients remains highly sought after. In this review, we discuss the recent clinical trial results of pembrolizumab, nivolumab, and atezolizumab for NSCLC, and the significance of companion diagnostic testing for tumor PD-L1 expression. BioMed Central 2016-08-16 /pmc/articles/PMC4986262/ /pubmed/27532023 http://dx.doi.org/10.1186/s40425-016-0153-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Clinical Trials Monitor Grigg, Claud Rizvi, Naiyer A. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? |
title | PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? |
title_full | PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? |
title_fullStr | PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? |
title_full_unstemmed | PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? |
title_short | PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? |
title_sort | pd-l1 biomarker testing for non-small cell lung cancer: truth or fiction? |
topic | Clinical Trials Monitor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986262/ https://www.ncbi.nlm.nih.gov/pubmed/27532023 http://dx.doi.org/10.1186/s40425-016-0153-x |
work_keys_str_mv | AT griggclaud pdl1biomarkertestingfornonsmallcelllungcancertruthorfiction AT rizvinaiyera pdl1biomarkertestingfornonsmallcelllungcancertruthorfiction |